XPO1 and acute myeloid leukemia: Then, in our center dataset, we divided the AML patients into the XPO1 high (top 25%, n = 13) and XPO1 low (bottom 75%, n = 40) expression groups, as well as the eIF4E high (top 25%, n = 13) and eIF4E low (bottom 75%, n = 40) expression groups, based on the XPO1 and eIF4E mRNA intensity, respectively.